S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,023.00 +0.94% CRUDE 81.77 +3.57%
Next Bullish Trade
Sign in
AMRX

Amneal Pharmaceuticals, Inc. AMRX

$17.85 -0.19 (-1.05%)
Extended · +1.85σ
Mkt cap $5.8B
P/E 48.6
Day $17.82 – $18.39
52wk $11.71 – $18.39
Avg vol
Beta
Div yld
Next earnings

Quick read

Plain English

Amneal Pharmaceuticals, Inc. is a healthcare company listed in the US.

AMRX last traded at $17.85, down 1.1% on the day; that's in the upper part of its 52-week range ($11.71–$18.39). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

132-Day Trend Zones

Full chart →
21 EMA +1 ATR +2 ATR −2 ATR
O H L C

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 69), the trend is strong (ADX 30), and volume is about normal (0.9×). On the business side, revenue is growing 4% year over year and the business keeps about 3 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI
69
0–100 · <30 oversold
Trend strength · ADX
30
>25 = strong trend
Volume vs avg
0.91×
1× = average
Stretch from avg
+1.8 ATR
− below · + above
Zone touches
0
tests of this zone
Suggested hold
3–30
bars (≈ days)
Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth
+3.9%
year over year
Free-cash-flow margin
3.4%
cash kept per $ of sales
Debt / equity
67.51
lower = less leveraged
P/E ratio
48.6
price ÷ yearly profit

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $-2.59 (fair range $-3–$28). The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)
$-2.59
Fair-value range
$-2.59 – $28.36
Verdict
Unknown
Accounting quality Weak
  • ✓ Current ratio 2.17 (antifragile)
  • ⚠ Debt exceeds cash
  • ⚠ Negative retained earnings
  • ⚠ Receivables growing faster than revenue

Price implies ~32% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

AMRX is a $5.8 billion company, priced at 49× last year's earnings, and the stock is trading near the top of its 52-week range.

Mkt cap $5.8B
P/E ttm 48.6
Fwd P/E
Beta
Day range $17.82 – $18.39
52w range $11.71 – $18.39
Avg vol
RSI(2) 68.9
ROE
Net mgn
FCF mgn 3.4%
Debt/Eq 67.51
Div yld
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Next earn
52-week range · today's price
$11.71$18.39

More on AMRX